Pablo Villoslada received his MD at the University of Santiago de Compostela (Spain) in 1990. He completed the speciality in neurology in 1995 at the Hospital Vall d?Hebron (Spain) and the PhD in Neuroimmunology in 1996 at the Autonomous University of Barcelona (Spain). He moved to the University of California, San Francisco (US) as a postdoctoral fellow returning to Barcelona in 1998 and he worked as Assistant Professor of the University of Navarra from 2001 to 2008. He became Group leader of the Neuroimmunology group of the Institute of Biomedical Research August Pi Sunyer (IDIBAPS) ? Hospital Clinic - University of Barcelona, Spain, in 2009. From 2014 to 2017 he became Adjunct Professor at the Department of Neurology at the University of California, San Francisco. From 2017 to 2018 he worked a Medical Director of Neuroinflammation at Genentech. Since October 2018 is adjunct professor at Stanford University. He is a serial entrepreneur, having founded Health Engineering (imaging software) and Bionure (drug development CNS), and being venture partner with Alta Life Sciences and Spire Bioventure. He joined the neurosciences team at Stanford University in October 2018.
Pablo Villoslada has been active in the Neurosciences and brain diseases research for more than 20 years contributing to the application of systems biology to neurological diseases, development of new therapies or biomarkers for Multiple Sclerosis and neurodegenerative diseases, and developing new neuroimaging technologies for monitoring brain diseases. He has published more than 170 scientific articles in journals in the field of neurology and has been granted 9 patents in biomarkers and new therapies for brain diseases. He has also obtained 5 EU grants and several others from international foundations.